|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dent R, Valentini A, Hanna W, Rawlinson E,
Rakovitch E, Sun P and Narod SA: Factors associated with breast
cancer mortality after local recurrence. Curr Oncol. 21:e418–e425.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fischgräbe J and Wülfing P: Targeted
therapies in breast cancer: Established drugs and recent
developments. Curr Clin Pharmacol. 3:85–98. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Frödin M and Gammeltoft S: Role and
regulation of 90 kDa ribosomal S6 kinase (RSK) in signal
transduction. Mol Cell Endocrinol. 151:65–77. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anjum R and Blenis J: The RSK family of
kinases: Emerging roles in cellular signalling. Nat Rev Mol Cell
Biol. 9:747–758. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nebreda AR and Gavin AC: Perspectives:
Signal transduction. Cell survival demands some Rsk. Science.
286:1309–1310. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yntema HG, van den Helm B, Kissing J, van
Duijnhoven G, Poppelaars F, Chelly J, Moraine C, Fryns JP, Hamel
BC, Heilbronner H, et al: A novel ribosomal S6-kinase (RSK4;
RPS6KA6) is commonly deleted in patients with complex X-linked
mental retardation. Genomics. 62:332–343. 1999. View Article : Google Scholar
|
|
8
|
Roux PP and Blenis J: ERK and p38
MAPK-activated protein kinases: A family of protein kinases with
diverse biological functions. Microbiol Mol Biol Rev. 68:320–344.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roux PP, Ballif BA, Anjum R, Gygi SP and
Blenis J: Tumor-promoting phorbol esters and activated Ras
inactivate the tuberous sclerosis tumor suppressor complex via p90
ribosomal S6 kinase. Proc Natl Acad Sci USA. 101:13489–13494. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang X, Matsuda K, Bialek P, Jacquot S,
Masuoka HC, Schinke T, Li L, Brancorsini S, Sassone-Corsi P, Townes
TM, et al: ATF4 is a substrate of RSK2 and an essential regulator
of osteoblast biology; implication for Coffin-Lowry syndrome. Cell.
117:387–398. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Woo MS, Ohta Y, Rabinovitz I, Stossel TP
and Blenis J: Ribosomal S6 kinase (RSK) regulates phosphorylation
of filamin A on an important regulatory site. Mol Cell Biol.
24:3025–3035. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dümmler BA, Hauge C, Silber J, Yntema HG,
Kruse LS, Kofoed B, Hemmings BA, Alessi DR and Frödin M: Functional
characterization of human RSK4, a new 90-kDa ribosomal S6 kinase,
reveals constitutive activation in most cell types. J Biol Chem.
280:13304–13314. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thakur A, Sun Y, Bollig A, Wu J, Biliran
H, Banerjee S, Sarkar FH and Liao DJ: Anti-invasive and
antimetastatic activities of ribosomal protein S6 kinase 4 in
breast cancer cells. Clin Cancer Res. 14:4427–4436. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
López-Vicente L, Armengol G, Pons B, Coch
L, Argelaguet E, Lleonart M, Hernández-Losa J, de Torres I and
Ramon y Cajal S: Regulation of replicative and stress-induced
senescence by RSK4, which is down-regulated in human tumors. Clin
Cancer Res. 15:4546–4553. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Elbashir SM, Lendeckel W and Tuschl T: RNA
interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev.
15:188–200. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sen GL and Blau HM: A brief history of
RNAi: The silence of the genes. FASEB J. 20:1293–1299. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Myers AP, Corson LB, Rossant J and Baker
JC: Characterization of mouse Rsk4 as an inhibitor of fibroblast
growth factor-RAS-extracellular signal-regulated kinase signaling.
Mol Cell Biol. 24:4255–4266. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Berns K, Hijmans EM, Mullenders J,
Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M,
Nijkamp W, Weigelt B, et al: A large-scale RNAi screen in human
cells identifies new components of the p53 pathway. Nature.
428:431–437. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thakur A, Rahman KW, Wu J, Bollig A,
Biliran H, Lin X, Nassar H, Grignon DJ, Sarkar FH and Liao JD:
Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in
breast cancer. Mol Cancer Res. 5:171–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sharp PA: RNA interference - 2001. Genes
Dev. 15:485–490. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hannon GJ and Rossi JJ: Unlocking the
potential of the human genome with RNA interference. Nature.
431:371–378. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stewart SA, Dykxhoorn DM, Palliser D,
Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, et
al: Lentivirus-delivered stable gene silencing by RNAi in primary
cells. RNA. 9:493–501. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McIntosh GG, Anderson JJ, Milton I,
Steward M, Parr AH, Thomas MD, Henry JA, Angus B, Lennard TW and
Horne CH: Determination of the prognostic value of cyclin D1
overexpression in breast cancer. Oncogene. 11:885–891.
1995.PubMed/NCBI
|
|
24
|
Vos CB, Ter Haar NT, Peterse JL,
Cornelisse CJ and van de Vijver MJ: Cyclin D1 gene amplification
and overexpression are present in ductal carcinoma in situ of the
breast. J Pathol. 187:279–284. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oyama T, Kashiwabara K, Yoshimoto K,
Arnold A and Koerner F: Frequent overexpression of the cyclin D1
oncogene in invasive lobular carcinoma of the breast. Cancer Res.
58:2876–2880. 1998.PubMed/NCBI
|
|
26
|
Bilalović N, Vranić S, Basić H, Tatarević
A and Selak I: Immunohistochemical evaluation of cyclin D1 in
breast cancer. Croat Med J. 46:382–388. 2005.
|
|
27
|
Niewiadomska H, Jeziorski A and Olborski
B: The expression of the proliferating antigen Ki67, PCNA and
products of suppressor gene p53 in primary invasive ductal breast
carcinoma. J Exp Clin Cancer Res. 17:503–510. 1998.
|
|
28
|
Zhou CJ, Zhang QH, Zhang TG, Sun SZ, Li H,
Wang Y and Liu ZY: Expression of ER, Ki-67 and cylinD1 in the
pre-cancerous breast of Chinese patients. Pathol Oncol Res.
15:153–158. 2009. View Article : Google Scholar
|
|
29
|
Shargh SA, Sakizli M, Khalaj V, Movafagh
A, Yazdi H, Hagigatjou E, Sayad A, Mansouri N, Mortazavi-Tabatabaei
SA and Khorram Khorshid HR: Downregulation of E-cadherin expression
in breast cancer by promoter hypermethylation and its relation with
progression and prognosis of tumor. Med Oncol. 31:2502014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Siitonen SM, Kononen JT, Helin HJ, Rantala
IS, Holli KA and Isola JJ: Reduced E-cadherin expression is
associated with invasiveness and unfavorable prognosis in breast
cancer. Am J Clin Pathol. 105:394–402. 1996.PubMed/NCBI
|
|
31
|
Furusato B, Mohamed A, Uhlén M and Rhim
JS: CXCR4 and cancer. Pathol Int. 60:497–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
